Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
boserolimab + pembrolizumab
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination involves **boserolimab (MK-5890)**, an investigational drug, and **pembrolizumab (MK-3475, Keytruda)**, a PD-1 inhibitor. Pembrolizumab works by blocking the PD-1 receptor on T cells, enhancing the immune response against cancer cells. Boserolimab's specific mechanism is not detailed in the available data, but it is being studied in combination with pembrolizumab for advanced solid tumors, including non-small cell lung cancer and triple-negative breast cancer.
- Other names
- pembrolizumab plus boserolimabpembrolizumab and boserolimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on boserolimab + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on boserolimab + pembrolizumab.